CEUS vs. AMRI for HCC Detection in Patients With Indeterminate Liver Nodules

The study will be conducted at the following locations: 1. UT Southwestern Medical Center 2. Parkland Health and Hospital System 3. University of Michigan Investigators will prospectively compare the performance of dynamic contrast enhanced abbreviated MRI (AMRI) and contrast-enhanced ultrasound for early-stage HCC detection in patients with indeterminate liver nodules.

Inclusion Criteria: * Child A or B cirrhosis from any etiology with at least one ILN on 4-phase CT, contrast- enhanced MRI, or contrast enhanced US but without HCC at baseline. * Adults 18 years old and above Exclusion Criteria: * Patients post liver transplantation * Patients with concurrent or prior HCC (LR-5 or biopsy proven) * other liver cancer including cholangiocarcinoma * Patients with any active extra-hepatic malignancy * Patients with significant comorbidity and limited life expectancy, e.g., stage D congestive heart failure, in whom surveillance is not warranted are also excluded given unlikely clinical benefit * Patients with contraindication to contrast-enhanced MRI or CEUS, including implanted medical devices that are considered MR unsafe and severe claustrophobia